GB2302808A - Propylene glycol with low potency corticosteroids for topical treatment of the scalp - Google Patents

Propylene glycol with low potency corticosteroids for topical treatment of the scalp Download PDF

Info

Publication number
GB2302808A
GB2302808A GB9513553A GB9513553A GB2302808A GB 2302808 A GB2302808 A GB 2302808A GB 9513553 A GB9513553 A GB 9513553A GB 9513553 A GB9513553 A GB 9513553A GB 2302808 A GB2302808 A GB 2302808A
Authority
GB
United Kingdom
Prior art keywords
propylene glycol
scalp
composition according
low potency
dandruff
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB9513553A
Other versions
GB9513553D0 (en
Inventor
Michael Potts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surtech International Ltd
Original Assignee
Surtech International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surtech International Ltd filed Critical Surtech International Ltd
Priority to GB9513553A priority Critical patent/GB2302808A/en
Publication of GB9513553D0 publication Critical patent/GB9513553D0/en
Publication of GB2302808A publication Critical patent/GB2302808A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/006Antidandruff preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Propylene glycol in synergistic combination with a low potency corticosteroid, i.e. hydrocortisone is topically applied to treat scaling conditions of the scalp, i.e. dandruff, seborrhoeic dermatitis and psoriasis. The compositions may be in the form of solutions, lotions, creams, ointments or gels and may also contain water, isopropyl alcohol and citric acid.

Description

METHOD AND COMPOSITION FOR PREVENTION AND/OR TREATMENT OF DANDRUFF AND SEBORRHOEIC DERMATITIS This invention relates to a method and composition for the prevention and/or treatment of scaling conditions of the scalp, such as dandruff, seborrhoeic dermatitis and psoriasis.
Previously known methods for preventing and treating dandruff generally involve applying to the scalp various anti-dandruff agents contained in lotions, gels and shampoos. Examples of such anti-dandruff agents include sulphur and selenium compounds, zinc pyrrithione and bacteriostatic and bactericidal agents such as, for example, hexachlorophene. In many individuals, the use of such antidandruff agents can give rise to adverse reactions, for example allergic reactions and erythematous lesions. Consequently, known anti-dandruff agents cannot be used in the long term and it is frequently found that dandruff symptoms recur.
Known anti-dandruff agents are often difficult to formulate into cosmetically acceptable compositions.
Known treatments for seborrhoeic dermatitis and psoriasis generally involve the use of corticosteroids or other pharmacologically active agents which have a profound metabolic effect. However in order to be effective, known corticosteroids formulation either need to contain a corticosteroid which has an inherently high level of corticosteroid activity, for example Betnovate, Dermovate, Diprosalic or Locoid, or the corticosteroid needs to be present in a high concentration. There is an awareness that these potent products, in the form of alcoholic based scalp lotions, need to be used with caution and sparingly.
Thus the risk of side effects run parallel with the strength of the steroid, the duration of therapy and the site treated. For example, the face, genital area and intertriginous areas will absorb more steroids than other areas. In the UK topical corticosteroids are listed in terms of potency; mild, moderate, potent and very potent. The potent and very potent steroids should be carefully monitored and limited to a few weeks use when a milder steroid should be substituted if possible.
Cutaneous side effects may be apparent after two weeks.
Only mild steroids should be used in children to avoid the potential of growth retardation and possible long lasting cosmetic disfiguration.
UK Patent No. GB 2,205,743 described the finding that propylene glycol is effective as an anti-dandruff agent and that a significant anti-dandruff effect may be observed following application of propylene glycol to the scalp, e.g. in the form of a lotion, gel or shampoo. Propylene glycol, when used in accordance with the teachings of GB 2,205,743, avoided undesirable side effects which occur following use of known anti-dandruff agents.
Propylene glycol has hitherto also been described for use as a diluent, thinning agent or vehicle for various pharmaceutical products including such products intended for topical use. Thus US-A-3,984,866 describes the use of certain alpha-substituted carboxylic acid derivatives as active ingredients for treating keratinization defects.
It has now been found that by combining propylene glycol with a relatively low concentration of a weak corticosteroid (neither of which would in itself possess a substantial effect against scaling conditions of the scalp), a synergistically effective combination results. The preferred weak corticosteroid is hydrocortisone or a hydrocortisone salt.
Such combinations have been found to be especially effective against not only dandruff, but also more serious scaling conditions of the scalp, such as seborrhoeic dermatitis and psoriasis.
A possible reason for the actions of the combination therapy of the invention is that combinations of propylene glycol and the weak corticosteroid have enhanced activity against Pityrosporum ovale, an organism that is now thought to be implicated as an aetiological agent responsible for both psoriasis and seborrhoeic dermatitis and possibly also dandruff.
According to one aspect of the invention there is provided a composition for use in the treatment of scaling conditions of the scalp, including dandruff, seborrhoeic dermatitis and psoriasis which comprises as active ingredients, propylene glycol and a low potency corticosteroid, together with a topically acceptable excipient.
Preferably the concentration of propylene glycol is from 5 to 50 wt %, most preferably from 5 to 20 wt %, especially 8 to 12 wt %.
The low potency corticosteroid is preferably present in a concentration of from 0.2 to 3 wt %, most preferably from 0.5 to 1 wt %.
The compositions according to the invention may be formulated in the form of solutions, lotions, creams, ointments or gels suitable for topical application.
Compositions according to the invention may contain any conventional incidental adjuvants, for example, emollients, thickening agents, perfumes, colouring agents, stabilising agents, pH-adjusting agents and preservatives as well as water and/or a C14 alkanol.
According to a further aspect of the invention there is provided a method of treating dandruff and/or seborrhoeic dermatitis and/or psoriasis which comprises applying a composition according to the invention to the affected region.
In carrying out the method of the invention, the compositions may be applied to the affected region at regular intervals of, for example, 1-4 times daily.
The following examples illustrate compositions according to the invention HYDROCORTISONE SCALP LOTION Ingredient % Composition Purified Water 28.50 Klucel HF 0.50 Propylene Glycol 10.00 Isopropyl Alcohol (99%) 60.00 Hydrocortisone 1.00 Citric Acid qs

Claims (10)

1. A composition for use in the treatment of scaling conditions of the scalp, including dandruff, seborrhoeic dermatitis and psoriasis which comprises as active ingredients, propylene glycol and a low potency corticosteroid, together with a topically acceptable excipient.
2. A composition according to Claim 1 wherein the propylene glycol is present in a concentration of from 5 to 50 wt %.
3. A composition according to Claim 2 wherein the propylene glycol is present in a concentration of from 5 to 20 wt %.
4. A composition according to any preceding claim wherein the propylene glycol is present in a concentration of from 8 to 12 wt %.
5. A composition according to Claim 4 wherein the low potency corticosteroid is present in a concentration of from 0.2 to 3 wt %.
6. A composition according to any preceding claim wherein the topically acceptable excipients comprise water and/or a CiA alkanol.
7. A composition according to any preceding claim in the form of a solution, lotion, cream, ointment or gel.
8. A composition according to any of Claims 1 to 7 in the form of a shampoo.
9. A composition according to any preceding claim wherein the low potency ccorticosteroid comprises hydrocortisone or a hydrocortisone salt.
10. A method for the prevention and/or treatment of scaling conditions of the scalp, including dandruff, seborrhoeic dermatitis and psoriasis which comprises applying to the scalp a composition as claimed in any preceding claim.
GB9513553A 1995-07-04 1995-07-04 Propylene glycol with low potency corticosteroids for topical treatment of the scalp Withdrawn GB2302808A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB9513553A GB2302808A (en) 1995-07-04 1995-07-04 Propylene glycol with low potency corticosteroids for topical treatment of the scalp

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9513553A GB2302808A (en) 1995-07-04 1995-07-04 Propylene glycol with low potency corticosteroids for topical treatment of the scalp

Publications (2)

Publication Number Publication Date
GB9513553D0 GB9513553D0 (en) 1995-09-06
GB2302808A true GB2302808A (en) 1997-02-05

Family

ID=10777073

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9513553A Withdrawn GB2302808A (en) 1995-07-04 1995-07-04 Propylene glycol with low potency corticosteroids for topical treatment of the scalp

Country Status (1)

Country Link
GB (1) GB2302808A (en)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1543907A (en) * 1975-02-19 1979-04-11 Dermal Labor Ltd Steroid compositions
US4213979A (en) * 1978-12-18 1980-07-22 Plough, Inc. Stable sprayable hydrocortisone product
US4246261A (en) * 1979-08-09 1981-01-20 Scott Eugene J Van Additives enhancing topical corticosteroid action
US4289764A (en) * 1979-12-04 1981-09-15 Drythanol Ltd. Steroid compositions
US4305936A (en) * 1980-10-09 1981-12-15 Dermik Laboratories Topical corticosteroid formulations
WO1987004617A1 (en) * 1986-02-04 1987-08-13 Sven Moberg Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
JPS62292716A (en) * 1986-06-11 1987-12-19 Kao Corp Ointment base
US4797402A (en) * 1987-06-02 1989-01-10 Dorsey Kenneth E Cooling anti-itch skin preparations
US4853379A (en) * 1982-12-09 1989-08-01 Societe Anonyme Dite: L'oreal Stable hydrocortisone-based composition for use in local corticotherapy
WO1994006434A1 (en) * 1992-09-11 1994-03-31 Sandra Brown Method and composition for the treatment of hair loss
WO1996020712A1 (en) * 1994-12-30 1996-07-11 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1543907A (en) * 1975-02-19 1979-04-11 Dermal Labor Ltd Steroid compositions
US4213979A (en) * 1978-12-18 1980-07-22 Plough, Inc. Stable sprayable hydrocortisone product
US4246261A (en) * 1979-08-09 1981-01-20 Scott Eugene J Van Additives enhancing topical corticosteroid action
US4289764A (en) * 1979-12-04 1981-09-15 Drythanol Ltd. Steroid compositions
US4305936A (en) * 1980-10-09 1981-12-15 Dermik Laboratories Topical corticosteroid formulations
US4853379A (en) * 1982-12-09 1989-08-01 Societe Anonyme Dite: L'oreal Stable hydrocortisone-based composition for use in local corticotherapy
WO1987004617A1 (en) * 1986-02-04 1987-08-13 Sven Moberg Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
JPS62292716A (en) * 1986-06-11 1987-12-19 Kao Corp Ointment base
US4797402A (en) * 1987-06-02 1989-01-10 Dorsey Kenneth E Cooling anti-itch skin preparations
WO1994006434A1 (en) * 1992-09-11 1994-03-31 Sandra Brown Method and composition for the treatment of hair loss
WO1996020712A1 (en) * 1994-12-30 1996-07-11 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAS ONLINE Abstract Accession No. 109:134984 & JP 62 292 716 A *

Also Published As

Publication number Publication date
GB9513553D0 (en) 1995-09-06

Similar Documents

Publication Publication Date Title
US6667045B2 (en) Topical applications for skin treatment
JP4681087B2 (en) Combination of acidic protease enzyme and acidic buffer and use thereof
US6096326A (en) Skin care compositions and use
CA1279576C (en) Treatment of skin disorders
US8846646B2 (en) Topical treatment of skin infection
US20060159714A1 (en) Use of an antioxidant in a dermatological and/or cosmetic composition
US20030194446A1 (en) Zinc oxide compositions for dermatheraputics
US20140199413A1 (en) Melatonin and an antimicrobial or antibacterial agent for the treatment of acne
WO1994009755A1 (en) Method and composition for prevention and/or treatment of dandruff and seborrhoeic dermatitis
US5667790A (en) Aluminum chlorhydrate as a treatment for acne and rosacea
EP3781152B1 (en) Topical formulations comprising strontium and methylsulfonylmethane (msm) and their use for skin treatment
DK165938B (en) TOPIC AGENT FOR TREATMENT OF NON-INFLAMMATORY ACNE
AU698830B2 (en) Compositions for the treatment of skin conditions
JPH11100324A (en) Composition for treating pimple
GB2302808A (en) Propylene glycol with low potency corticosteroids for topical treatment of the scalp
US6485714B1 (en) Use of salicylic acid for regulating hyperpigmented spots
KR20010073220A (en) Fluticasone Lotion Having Improved Vasoconstrictor Activity
EP0086228B1 (en) Use of carbamide peroxide for the manufacture of a medicament for treatment of acne vulgaris
JP2016501236A (en) Methods for prevention and treatment of inflammatory skin conditions
WO2003097070A1 (en) The pharmaceutical composition comprising a corticosteroid and an antiseptic
JP2004307372A (en) External preparation for acne, use of plum extract and germicidal and antibacterial agent
GB2302807A (en) Method and composition for treating atopic eczema
US20080312245A1 (en) Methods and compositions for treating acne and other infectious diseases
JPH10273422A (en) Cosmetic for hair
JPH0995421A (en) Beautifier for external use

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)